Collaboration - April 20, 2015
PCI Partners With U.S. Firm
Norway’s PCI Biotech is initiating a pre-clinical research collaboration with American biotechnology company RXi Pharmaceuticals. The purpose of the pre-clinical research collaboration “is to utilize the companies’ complementary scientific platforms to explore potential synergies,” according to information from PCI Biotech. The partnership will evaluate technology compatibility based on in vitro and in vivo studies. Each […]
Collaboration - April 15, 2015
LDC, Astra Expand Alliance
The Lead Discovery Center GmbH (LDC) and AstraZeneca have expanded their alliance to discover new medicines for the treatment of diseases with high unmet medical need, according to report published on BioSpace.com. Through an additional three-year period of collaboration, AstraZeneca expects to provide an extended set of high-quality compounds to the LDC’s internal screening collection […]
Collaboration - April 2, 2015
New Partner for NeuroVive
NeuroVive Pharmaceutical AB has formed a new partnership with the UK’s Isomerase Therapeutics to pursue a new phase based on new molecules for its stroke medication candidate NVPO14. NeuroVive ended its previous collaboration with to-BBB of the Netherlands at the end of 2014, following to-BBB’s restructuring and liquidation. The partnership with to-BBB was funded through a grant […]
Collaboration - April 1, 2015
Medicon Valley, U.S. Cluster Partner
The Medicon Valley group, which includes Copenhagen, the capital and Zealand regions of Denmark and the Skåne region in Sweden, has entered a partnership with the Massachusetts (U.S.) Life Science Cluster (MLSC) to develop new drugs and healthcare technology. Among the projects is an effort to develop a new drug for prostate cancer, which is […]
Collaboration - March 28, 2015
Astra, Innate Sign Agreement
Innate Pharma has signed a co-development and commercialization agreement with AstraZeneca and MedImmune, AstraZeneca’s wholly-owned subsidiary. The deal focuses on the development of anti-NKG2A antibody, IPH2201, also in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor created by MedImmune, to fight cancer. The compound IPH2201 currently is in Phase II development. Under the terms of […]
Collaboration - March 25, 2015
Denator, M4I to Collaborate
Denator AB has entered a two-year collaboration with the Maastricht MultiModal Molecular Imaging Institute (M4I) of Maastricht University, the Netherlands. As part of the collaboration, Denator will work closely with the M4I Division of Imaging Mass Spectrometry, headed by university professor Ron Heeren, to jointly develop and evaluate innovative sample stabilization approaches for clinical applications, […]
